Bipinkumar Amin

643 total citations
5 papers, 182 citations indexed

About

Bipinkumar Amin is a scholar working on Genetics, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Bipinkumar Amin has authored 5 papers receiving a total of 182 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Genetics, 4 papers in Pathology and Forensic Medicine and 2 papers in Oncology. Recurrent topics in Bipinkumar Amin's work include Chronic Lymphocytic Leukemia Research (4 papers), Lymphoma Diagnosis and Treatment (4 papers) and Multiple Myeloma Research and Treatments (2 papers). Bipinkumar Amin is often cited by papers focused on Chronic Lymphocytic Leukemia Research (4 papers), Lymphoma Diagnosis and Treatment (4 papers) and Multiple Myeloma Research and Treatments (2 papers). Bipinkumar Amin collaborates with scholars based in United States, Italy and France. Bipinkumar Amin's co-authors include William J. Gradishar, Luís Meza, Elyse E. Lower, P. Kelly Marcom, Dvorit Samid, Todd Hill, Nathan Fowler, Sonali M. Smith, Peter J. Rosen and Amanda F. Cashen and has published in prestigious journals such as Journal of Clinical Oncology and Blood.

In The Last Decade

Bipinkumar Amin

5 papers receiving 180 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bipinkumar Amin United States	5	121	91	68	28	27	5	182
Yazeed Sawalha United States	8	97 0.8×	99 1.1×	53 0.8×	24 0.9×	9 0.3×	43	169
Henriette W Berenschot Netherlands	6	103 0.9×	126 1.4×	62 0.9×	16 0.6×	8 0.3×	11	164
Jesse Shustik Canada	5	78 0.6×	114 1.3×	50 0.7×	26 0.9×	8 0.3×	11	142
Barbara Mankel Germany	6	72 0.6×	76 0.8×	36 0.5×	43 1.5×	13 0.5×	12	131
Ruben A. L. de Groen Netherlands	7	107 0.9×	132 1.5×	63 0.9×	28 1.0×	30 1.1×	16	202
Mitul Gandhi United States	8	127 1.0×	133 1.5×	80 1.2×	34 1.2×	7 0.3×	30	202
Susana Ben Neriah Canada	4	80 0.7×	134 1.5×	65 1.0×	18 0.6×	8 0.3×	5	158
Sandra Lockmer Sweden	5	154 1.3×	190 2.1×	80 1.2×	18 0.6×	14 0.5×	12	209
Takayasu Kato Japan	6	45 0.4×	94 1.0×	44 0.6×	32 1.1×	53 2.0×	25	159
Mu‐Chen Zhang China	7	109 0.9×	150 1.6×	42 0.6×	57 2.0×	25 0.9×	16	210

Countries citing papers authored by Bipinkumar Amin

Since Specialization

Citations

This map shows the geographic impact of Bipinkumar Amin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bipinkumar Amin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bipinkumar Amin more than expected).

Fields of papers citing papers by Bipinkumar Amin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bipinkumar Amin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bipinkumar Amin. The network helps show where Bipinkumar Amin may publish in the future.

Co-authorship network of co-authors of Bipinkumar Amin

This figure shows the co-authorship network connecting the top 25 collaborators of Bipinkumar Amin. A scholar is included among the top collaborators of Bipinkumar Amin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bipinkumar Amin. Bipinkumar Amin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

5 of 5 papers shown

1.

Salles, Gilles, Nicole Lamanna, Bipinkumar Amin, et al.. (2014). A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib in combination with bendamustine and rituximab for previously untreated chronic lymphocytic leukemia.. Journal of Clinical Oncology. 32(15_suppl). TPS7123–TPS7123. 9 indexed citations

2.

Fowler, Nathan, Brad S. Kahl, Peter P. Lee, et al.. (2011). Bortezomib, Bendamustine, and Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma: The Phase II VERTICAL Study. Journal of Clinical Oncology. 29(25). 3389–3395. 81 indexed citations

3.

Rosen, Peter J., Stephen J. Noga, Nathan Fowler, et al.. (2009). Bortezomib, bendamustine, and rituximab in patients (pts) with relapsed (rel) or refractory (ref) follicular lymphoma (FL): Dose-finding results of the VERTICAL study. Journal of Clinical Oncology. 27(15_suppl). 8550–8550. 8 indexed citations

4.

Fowler, Nathan, Brad S. Kahl, Peter J. Rosen, et al.. (2009). Bortezomib, Bendamustine, and Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma: Encouraging Activity in the Phase 2 VERTICAL Study.. Blood. 114(22). 933–933. 14 indexed citations

5.

Gradishar, William J., Luís Meza, Bipinkumar Amin, et al.. (2004). Capecitabine Plus Paclitaxel As Front-Line Combination Therapy for Metastatic Breast Cancer: A Multicenter Phase II Study. Journal of Clinical Oncology. 22(12). 2321–2327. 70 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact